Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023)
Alkermes (ALKS) posted quarterly Liabilities from Discontinued Operations of 4542000.0 for Q4 2023, down 66.46% year-over-year from 13542000.0 in Q4 2022, and down 66.46% quarter-over-quarter from 13542000.0 in Q4 2022.
Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Alkermes (ALKS) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 4542000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Liabilities from Discontinued Operations fell 66.46% year-over-year to 4542000.0; the TTM figure through Dec 2023 stood at 4542000.0 (down 66.46% YoY), while the FY2023 annual figure was 4542000.0, down 66.46% from the prior year.
- Liabilities from Discontinued Operations slipped to 4542000.0 in Q4 2023 per ALKS's latest filing, from 13542000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 13542000.0 in Q4 2022 and bottomed at 4542000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.54 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 13.54 Mn |
| Dec 31, 2022 | 13.54 Mn |